Cell & Gene The Podcast: Inside SA¹ú¼Ê´«Ã½ Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.

Related News

Press Releases

SA¹ú¼Ê´«Ã½ Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in SA¹ú¼Ê´«Ã½’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Podcasts

Forging the future of cell therapy: Bayer and SA¹ú¼Ê´«Ã½’s unique journey

June 5, 2025
Press Releases

SA¹ú¼Ê´«Ã½ Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in SA¹ú¼Ê´«Ã½’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Podcasts

Forging the future of cell therapy: Bayer and SA¹ú¼Ê´«Ã½’s unique journey

June 5, 2025